EU criticises 'hasty' UK approval of Covid-19 vaccine | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Tuesday
December 05, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Food
    • Habitat
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
TUESDAY, DECEMBER 05, 2023
EU criticises 'hasty' UK approval of Covid-19 vaccine

World+Biz

Reuters
02 December, 2020, 08:00 pm
Last modified: 02 December, 2020, 08:02 pm

Related News

  • AI could judge if user is of porn-watching age under new UK guidance
  • UK announces stricter visa requirements to reduce migration
  • IFIC Bank organized Remittance Road show in UK
  • EU wants Bangladesh to act on labour rights as pledged
  • EU representatives meet CEC

EU criticises 'hasty' UK approval of Covid-19 vaccine

The move to grant emergency authorisation to the Pfizer/BioNTech vaccine has been seen by many as a political coup for UK Prime Minister Boris Johnson, who has led his country out of the EU and faced criticism for his handling of the pandemic

Reuters
02 December, 2020, 08:00 pm
Last modified: 02 December, 2020, 08:02 pm
The EU flag is reflected in a drop on a syringe needle in this illustration Photo: Reuters
The EU flag is reflected in a drop on a syringe needle in this illustration Photo: Reuters

The European Union criticised Britain's rapid approval of Pfizer and BioNTech's Covid-19 vaccine on Wednesday, saying its own procedure was more thorough after Britain became the first western country to endorse a Covid-19 shot.

The move to grant emergency authorisation to the Pfizer/BioNTech vaccine has been seen by many as a political coup for UK Prime Minister Boris Johnson, who has led his country out of the EU and faced criticism for his handling of the pandemic.

The decision was made under an ultra-fast, emergency approval process, which allowed the British drugs regulator to temporarily authorise the vaccine only ten days after it began examining data from large-scale trials.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

In an unusually blunt statement, the European Medicines Agency (EMA), which is in charge of approving Covid-19 vaccines for the EU, said its longer approval procedure was more appropriate as it was based on more evidence and required more checks than the emergency procedure chosen by Britain.

The agency said on Tuesday it would decide by Dec. 29 whether to provisionally authorise the vaccine from US drugmaker Pfizer and its German partner BioNTech.

A spokesman for the European Commission, the EU executive, said the EMA's procedure was "the most effective regulatory mechanism to grant all EU citizens' access to a safe and effective vaccine," as it was based on more evidence.

June Raine, the head of Britain's Medicines and Healthcare products Regulatory Agency (MHRA), defended its decision.

"The way in which the MHRA has worked is equivalent to all international standards," she said.

"Our progress has been totally dependent on the availability of data in our rolling review and our rigorous assessment and independent advice we have received," she added.

The EMA started a rolling review of preliminary data from Pfizer trials on Oct. 6, an emergency procedure aimed at speeding up possible approval, which usually takes at least seven months from the reception of full data.

The UK regulator launched its own rolling review on Oct. 30 and analysed less data than made available to the EMA.

"The idea is not to be first but to have a safe and effective vaccine," Germany's Health Minister Jens Spahn told a news conference.

Asked about the emergency procedure used by Britain, he said EU countries had opted for a more thorough procedure to boost confidence in vaccines.

"If you evaluate only the partial data as they are doing they also take a minimum of risk," the EMA's former head Guido Rasi told Italian radio.

"Personally I would have expected a robust review of all available data, which the British government has not done to be able to say that without Europe you come first," he added.

'PROBLEMATIC'

EU lawmakers were even more explicit in their criticism of Britain's move.

"I consider this decision to be problematic and recommend that the EU Member States do not repeat the process in the same way," said Peter Liese, an EU lawmaker who is a member of German Chancellor Angela Merkel's party.

"A few weeks of a thorough examination by the European Medicines Agency is better than a hasty emergency marketing authorisation of a vaccine," said Liese, who represents the centre-right grouping, the largest in the EU Parliament.

Under EU rules, the Pfizer vaccine must be authorised by the EMA, but EU countries can use an emergency procedure that allows them to distribute a vaccine at home for temporary use.

Britain is still subject to EU rules until it fully leaves the bloc at the end of the year.

"There is an obvious global race to get the vaccine on the market as fast as possible," said Tiemo Wolken, an EU lawmaker from the socialist grouping, the second largest in the Parliament.

"However, I do believe that it is better to take the time and make sure that the quality, effectiveness and safety is guaranteed and matches our EU standards." 

covid-19 vaccine / EU / UK

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo: Collected
    Bangladesh to ask WB for $250m more in budget support
  • This file photo from December 2019 shows a rider driving his motorcycle through cold wind and fog. A scene not yet visible this year. Photo: Mumit M
    Why is 'winter not coming' yet
  • Dollar pressure rises as short-term foreign debt drops $300m in October
    Dollar pressure rises as short-term foreign debt drops $300m in October

MOST VIEWED

  • LPG cylinders. Photo: Courtesy
    12kg LPG cylinder price up Tk23
  • For the first time, Bangladesh seeks foreign loans to support Rohingyas
    For the first time, Bangladesh seeks foreign loans to support Rohingyas
  • Photo: Collected
    Indonesia volcano erupts, spews ash 3 km into sky
  • External trade through Islamic banks in decline
    External trade through Islamic banks in decline
  • Halal products export receives boost with new policy, but more is required
    Halal products export receives boost with new policy, but more is required
  • Exports up 27% in Nov as peak festival sales begin in West
    Exports up 27% in Nov as peak festival sales begin in West

Related News

  • AI could judge if user is of porn-watching age under new UK guidance
  • UK announces stricter visa requirements to reduce migration
  • IFIC Bank organized Remittance Road show in UK
  • EU wants Bangladesh to act on labour rights as pledged
  • EU representatives meet CEC

Features

Exploring door designs: Redefining spaces and experiences

Exploring door designs: Redefining spaces and experiences

41m | Habitat
A brain drain query: Why do they leave?

A brain drain query: Why do they leave?

5h | Panorama
The school has been flooding since June 2007 and the water level is rising every year. PHOTO: COURTESY

Will Dubai pay heed to the suffering of Sultan Al Nahyan School students in Bangladesh?

5h | Panorama
Masud Ahmad has written one of the finest Bangla novels in recent times, titled ‘Kanchanfuler Kobi,’ centred around the life and works of eminent poet Jibanananda Das. Photo: Rajib Dhar

How little-known Masud Ahmad became the 'Shera Bangali'

1d | Panorama

More Videos from TBS

November export earnings up 27 percent over previous month: EPB

November export earnings up 27 percent over previous month: EPB

1h | TBS Economy
Amitabh Bachchan's assets worth Rs 3,700 crore divided

Amitabh Bachchan's assets worth Rs 3,700 crore divided

46m | TBS Entertainment
External trade through Islamic banks in decline

External trade through Islamic banks in decline

2h | TBS Economy
How are people adapting to survive at the climate frontlines? | On the ground with Asif Saleh

How are people adapting to survive at the climate frontlines? | On the ground with Asif Saleh

2h | TBS Stories
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]